Sec. 3. National institute of arthritis and musculoskeletal and skin diseases; scleroderma research expansion
205 words·~1 min read·
/bill/113/s/1239/is/section-3A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
The Director of The National Institute of Arthritis and Musculoskeletal and Skin Diseases shall expand, intensify, and coordinate the activities of the Institute with respect to scleroderma, with particular emphasis on the following areas: Research focused on the etiology of scleroderma and the development of new treatment options. Clinical research to evaluate new treatments options. Basic research on the relationship between scleroderma and secondary conditions such as pulmonary hypertension, gastroparesis, Raynaud’s phenomenon, Sjögren’s Syndrome (and other diseases as determined by the Director).
Establishment of scleroderma patient registries, including family and childhood onset registries. Support for training of new clinicians and investigators with expertise in scleroderma. As a part of the biennial report made under section 403 of the Public Health Service Act ( 42 U.S.C. 283 ), the Secretary shall include information on the status of scleroderma research at the National Institutes of Health. For the purpose of carrying out subsection (a), there are authorized to be appropriated $25,000,000 in fiscal year 2014, $30,000,000 in fiscal year 2015, and $35,000,000 in fiscal year 2016.
Of the amounts authorized to be appropriated under paragraph (1), not more than 15 percent shall be reserved for the training of qualified health professionals in biomedical research focused on scleroderma.
Connectionstraces to 1
Traces to 1 document
Citation graph
cites case law
Sec. 3
National institute of arthritis and musculoskeletal and skin diseases; scleroderma research expansion
Cites 1Cited by 0 across 0 sources